Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.

Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.

Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.

Radiotherapy at a dose of 40 Gy, delivered in 20 fractions over 4 weeks.